Termo is a technology company.
Termo has raised $19.0M across 2 funding rounds.
Termo has raised $19.0M in total across 2 funding rounds.
Termo has raised $19.0M in total across 2 funding rounds.
Termo's investors include 360 Capital Partners, CDP Venture Capital, StartupGym, Unruly Capital.
Terumo Corporation is a global medical technology company founded in 1921, headquartered in Tokyo, Japan, and publicly traded on the Tokyo Stock Exchange (TSE:4543).[1][2][3] With over 30,000 employees and operations in more than 160 countries, it manufactures and sells innovative medical devices and equipment, generating $6.8 billion in revenue in 2024.[1][2] Terumo's portfolio spans three main segments: Cardiac and Vascular (e.g., devices for heart-lung support during surgery, stents, catheters), Medical Care Solutions (e.g., neurovascular, hospital care, diabetes management, peritoneal dialysis), and Blood and Cell Technologies (e.g., blood processing, transfusion systems, cell therapy).[2][3][5]
The company serves healthcare providers, blood centers, hospitals, biotech firms, and research institutions worldwide, addressing critical needs in cardiovascular care, blood management, and regenerative medicine.[2][5] Its growth is driven by a century-long commitment to "Contributing to Society through Healthcare," with pivotal expansions into global markets and acquisitions enhancing its leadership in minimally invasive and life-support technologies.[1][3]
Terumo was founded in 1921 in Japan as the Red Line Thermometer Corporation by a group of medical scientists, led by Dr. Shibasaburo Kitasato, to produce reliable clinical thermometers after World War I disrupted imports.[1][3][5][6] The first product, "Jintan Taionkei," marked Japan's entry into domestic thermometer manufacturing, laying the foundation for broader healthcare contributions.[3][6]
From the 1960s-1970s, Terumo diversified into medical disposables and expanded globally, opening its first U.S. office in 1971 and subsidiaries in Europe, Asia, and beyond.[3][6] Key pivots included entering artificial organs in the 1980s with innovations like the world's first microporous hollow fiber membrane oxygenator and dialyzer.[6] The 1990s-2000s saw aggressive growth through acquisitions, such as Vascutek (2002), MicroVention (2006), Harvest Technologies (2007), and Bolton Medical (2018, leading to Terumo Aortic), transforming it from a thermometer maker into a diversified medtech giant.[3][6]
Terumo rides the wave of aging populations, rising chronic diseases, and advances in minimally invasive surgery and cell therapies, where demand for cardiovascular devices, blood management, and regenerative treatments surges amid global healthcare spending projected to exceed $10 trillion by 2026.[1][2][5] Timing favors its 100-year legacy: post-WWII import independence evolved into leadership during medtech globalization, with acquisitions aligning perfectly with trends in precision medicine and endovascular interventions.[3][6]
Market forces like increasing catheterizations, cell therapy adoption (e.g., for cancer), and needs in emerging markets (Asia, India) propel growth; Terumo influences the ecosystem by setting standards in blood processing and partnering with biotechs, enabling safer transfusions and novel therapies for millions.[2][5] Its Japanese precision engineering combined with U.S./European footholds positions it as a bridge between Eastern manufacturing scale and Western innovation hubs.[1][3]
Terumo is poised for accelerated growth through cell/gene therapy expansion and aortic/vascular innovations, leveraging its Terumo BCT arm to capitalize on blood-based treatments becoming standard care.[5][8] Trends like AI-integrated devices, personalized medicine, and APAC demand will shape its path, potentially boosting revenue via new acquisitions and digital health integrations.[1][2]
Its influence may evolve from device supplier to ecosystem enabler, fostering regenerative breakthroughs—echoing its thermometer origins by again transforming everyday healthcare tools into life-changing technologies.[3][6]
Termo has raised $19.0M across 2 funding rounds. Most recently, it raised $9.0M Series C in December 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2021 | $9.0M Series C | 360 Capital Partners, CDP Venture Capital, StartupGym, Unruly Capital | |
| Dec 1, 2020 | $10.0M Series B | 360 Capital Partners, CDP Venture Capital, StartupGym, Unruly Capital |